Tetrakis(p-Carboranylthio-Tetrafluorophenyl)Chlorin (TPFC): Application for Photodynamic Therapy and Boron Neutron Capture Therapy
- PMID: 28756849
- DOI: 10.1002/jps.24317
Tetrakis(p-Carboranylthio-Tetrafluorophenyl)Chlorin (TPFC): Application for Photodynamic Therapy and Boron Neutron Capture Therapy
Abstract
Carboranyl-containing chlorins have emerged as promising dual sensitizers for use in both photodynamic therapy (PDT) and boron neutron capture therapy (BNCT), by virtue of their known tumor affinity, low cytotoxicity in dark conditions, and their strong absorptions in the red region of the optical spectrum. Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC) is a new synthetic carboranyl-containing chlorin of high boron content (24% by weight). To evaluate TPFC's applicability as sensitizer for both PDT and BNCT, we performed an in vitro and in vivo study using F98 rat glioma cells and F98 rat glioma-bearing brain tumor models. For the in vivo BNCT study, we used boronophenylalanine (BPA), which is currently used in clinical BNCT studies, via intravenous administration (i.v.) and/or used TPFC via convection-enhanced delivery (CED), a method for local drug infusion directly into the brain. In the in vitro PDT study, the cell surviving fraction following laser irradiation (9J/cm2) was 0.035 whereas in the in vitro BNCT study, the cell surviving fraction following neutron irradiation (thermal neutron=1.73×1012 n/cm2) was 0.04. In the in vivo BNCT study, the median survival time following concomitant administration of BPA (i.v.) and TPFC (CED) was 42days (95% confidence interval; 37-43days). © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.
Keywords: BNCT; CED; CNS; PDT; TPFC; absorption; blood–brain barrier; boron-containing chlorin; cell culture; osmotic pumps.
© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.
Similar articles
-
Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC): application for photodynamic therapy and boron neutron capture therapy.J Pharm Sci. 2015 Mar;104(3):962-70. doi: 10.1002/jps.24317. Epub 2014 Dec 26. J Pharm Sci. 2015. PMID: 25546823 Free PMC article.
-
Evaluation of a novel sodium borocaptate-containing unnatural amino acid as a boron delivery agent for neutron capture therapy of the F98 rat glioma.Radiat Oncol. 2017 Jan 23;12(1):26. doi: 10.1186/s13014-017-0765-4. Radiat Oncol. 2017. PMID: 28114947 Free PMC article.
-
Synthesis and biological investigations of tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC).Org Biomol Chem. 2008 Oct 21;6(20):3732-40. doi: 10.1039/b807836j. Epub 2008 Aug 18. Org Biomol Chem. 2008. PMID: 18843403
-
The radiation biology of boron neutron capture therapy.Radiat Res. 1999 Jan;151(1):1-18. Radiat Res. 1999. PMID: 9973079 Review.
-
Boron neutron capture therapy of primary and metastatic brain tumors.Mol Chem Neuropathol. 1994 Feb-Apr;21(2-3):139-54. doi: 10.1007/BF02815348. Mol Chem Neuropathol. 1994. PMID: 8086033 Review.
Cited by
-
Synthesis, Tumor Specificity, and Photosensitizing Efficacy of Erlotinib-Conjugated Chlorins and Bacteriochlorins: Identification of a Highly Effective Candidate for Photodynamic Therapy of Cancer.J Med Chem. 2021 Jan 14;64(1):741-767. doi: 10.1021/acs.jmedchem.0c01735. Epub 2021 Jan 5. J Med Chem. 2021. PMID: 33400524 Free PMC article.
-
Boron neutron capture therapy for malignant brain tumors.J Neurooncol. 2020 Aug;149(1):1-11. doi: 10.1007/s11060-020-03586-6. Epub 2020 Jul 16. J Neurooncol. 2020. PMID: 32676954 Review.
-
Fluorinated porphyrinoids as efficient platforms for new photonic materials, sensors, and therapeutics.Org Biomol Chem. 2016 Jan 14;14(2):389-408. doi: 10.1039/c5ob01839k. Org Biomol Chem. 2016. PMID: 26514229 Free PMC article. Review.
-
Folate receptor-targeted novel boron compound for boron neutron capture therapy on F98 glioma-bearing rats.Radiat Environ Biophys. 2019 Mar;58(1):59-67. doi: 10.1007/s00411-018-0765-2. Epub 2018 Nov 24. Radiat Environ Biophys. 2019. PMID: 30474719
LinkOut - more resources
Full Text Sources
